Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2019, Vol. 24 ›› Issue (8): 933-937.doi: 10.12092/j.issn.1009-2501.2019.08.014

Previous Articles     Next Articles

Effects of EPO on serum calcitonin gene-related peptide in patients with acute spinal cord injury

LIU Yadong 1, LU Xiaowei 2, LIU Zhigang 3   

  1. 1 Department of Bone Surgery, Sinopharm Dongfeng General Hospital, Shiyan 442008, Hubei, China; 2 Heart Function Examination Room, Sinopharm Dongfeng General Hospital, Shiyan 442008, Hubei, China; 3 Department of Orthopedics, the Third Hospital of Wuhan, Wuhan 430074, Hubei, China
  • Received:2019-01-09 Revised:2019-07-08 Online:2019-08-26 Published:2019-08-30

Abstract:

AIM: To investigate the effects of erythropoietin (EPO) on serum calcitonin gene-related peptide (CGRP) in patients with acute spinal cord injury. METHODS: From September 2013 to February 2018, 156 cases of patients with acute spinal cord injury who were selected for emergency department in our hospital were divided into 80 cases of EPO group and 76 cases of control group according to different treatment methods. The control group was given the treatment of methylprednisolone. The EPO group was given EPO treatment based on the treatment of the control group, and both groups were treated continuously for 4 weeks.RESULTS:The spinal nerve function scores of the two groups were significantly higher than those before treatment (P<0.05), and the EPO group were also significantly higher than the control group (P<0.05). The red blood cell and hemoglobin values in the EPO group were significantly higher than those before treatment (P<0.05), and were also higher than the control group (P<0.05). There was no significant difference in the red blood cell and hemoglobin values before and after treatment in the control group (P>0.05). The incidence of gastrointestinal bleeding, infection, liver and kidney dysfunction during the treatment of EPO group were 8.8%, and that of the control group were 9.2%, there was no significant difference compared between the two groups (P>0.05). The serum CGRP values of the two groups were significantly higher than those before treatment, and the EPO group was also significantly higher than the control group (P<0.05). CONCLUSION:EPO is safe for patients with acute spinal cord injury; it can promote the release of serum CGPR, improves the nutritional status of the body and the spinal nerve function of patients.

Key words: erythropoietin, acute spinal cord injury, calcitonin gene-related peptide, methylprednisolone

CLC Number: